Study pinpoints how a network of different proteins controls rest and activation
Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria. When ...
Tag: Immunotherapy
Exploring the potential of MSCs in cancer therapy
A new review was published in Oncotarget's Volume 15 on November 22, 2024, entitled "Mesenchymal stem cells – the secret agents of cancer ...
New immune therapy improves survival and reduces tumor burden in glioblastoma
The Wistar Institute's David B. Weiner, Ph.D. -; Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable ...
Phase 1 study finds serine- and glycine-free diet boosts immune response in colorectal cancer
Early trial shows a specialized diet enhances immune cell activity and improves the effectiveness of immunotherapy in colorectal cancer patients ...
Brain volume loss linked to Alzheimer's treatment may be caused by amyloid plaque removal
A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine
Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, ...
New approach reinvigorates exhausted T cells to improve tumor control
As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells ...
MD Anderson launches new institute for advancing cell therapy
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & ...
Understanding gut microbial imbalance in pancreatic cancer development and treatment
Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most lethal cancers, with an estimated five-year survival rate of ...
Combination therapy shows promising results in treating stage 3 melanoma
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of ...
